Understanding Proposition 65

Thank you

This webinar will provide a comprehensive overview of Proposition 65, including labeling requirements under the law, changes to the Clear and Reasonable Warning language requirements and the processes utilized by the Office of Environmental Health Hazard Assessment (OEHHA) to include a chemical on the list. Specific case examples will be provided where CHPA has worked with members to help them comply with the requirements under the law. Come prepared with questions and learn how to comply with this regulation.

Webinar Objectives

Provide an overview of how Proposition 65 affects consumer healthcare companies
Discuss specific examples of where CHPA has impacted Prop 65 regulations
Answer questions pertaining to the specifics of the law

Description

Provide an overview of how Proposition 65 affects consumer healthcare companies
Discuss specific examples of where CHPA has impacted Prop 65 regulations
Answer questions pertaining to the specifics of the law

Contributors

Dr. F. Jay Murray

Dr. F. Jay Murray is a toxicologist who heads the consulting firm of Murray & Associates in San Jose, California (1994 to present). He has over 40 years of experience in toxicology. Dr. Murray is a former member of the California Governor’s Scientific Advisory Panel for the Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65). In addition, he is a former member and chairperson of the Proposition 65 Scientific Advisory Panel’s Reproductive Toxicity Subcommittee.

Dr. Murray is a graduate of the University of Cincinnati College of Medicine (Ph.D. in toxicology), Stanford University Graduate School of Business, and Seton Hall University. He is board-certified by the American Board of Toxicology and a member of the Society of Toxicology. For 25 years, he was an Assistant Clinical Professor at the University of California, San Francisco. Dr. Murray was formerly employed by The Dow Chemical Company, Syntex Corporation (currently Roche Biosciences) and ENSR Corporation (currently AECOM). He is the author of over 160 scientific publications and presentations.
Jay Sirois

Jay Edward Sirois, Ph.D., is Vice President, Regulatory & Scientific Affairs at the Consumer Healthcare Products Association (CHPA), the 141-year-old national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines and dietary supplements. Dr. Sirois is responsible for regulatory and scientific affairs activities, including cooperative programs with the U.S. Food and Drug Administration, ingredient safety, and dietary supplement programs at CHPA. He is experienced in pharmaceutical, medical device, and dietary supplement regulatory affairs, pharmacovigilance, Rx-to-OTC switch, product safety, and clinical research.

Dr. Sirois is the current chair of the Dietary Supplements Sector of the USP Convention, and the former Chair of the steering committee for the Dietary Supplement Quality Collaborative, USP-led, multi-stakeholder and cross-sector collaborative efforts aimed at improving the quality and safety of products marketed as dietary supplements. He is a member of the Regulatory Affairs Professionals Society and is an ad hoc reviewer for the Journal of Dietary Supplements and Neurotoxicology. Dr. Sirois received his Ph.D. in Pharmacology and Toxicology (with a minor in Environmental Toxicology) from Michigan State University.

Thank you

Description

Contributors

Dr. F. Jay Murray

Jay Sirois